In addition, I-BET762 potently reduced MYC expression in LNCaP prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo [75]. The gene discussed is MYC; the disease is neoplasm.